reports
Coloplast A/S - Invitation to Coloplast's Meet the Management event on...
Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportuni...
- Jørgen Lian
Avance Gas (Hold, TP: NOK194.00) - Solid outlook being priced in
US production up 9% YOY since March has supported inventories and the arbitrage (currently implying cUSD95k/day rate). With current production levels, and VLGC deliveries to slow, we see an attractive earnings outlook backed by the FFA of USD70k/day for H2e. However, the LPG growth has outpaced crude oil (up 3%) and natural gas (up 0.5%) in the same period and EIA suggests it is set to decline. Still, we estimate total DPS of NOK30 in the next four quarters (18% of the current share price exclud...
Avance Gas Holding Ltd: Key information relating to return of capital ...
Avance Gas Holding Ltd: Key information relating to return of capital and dividend for the first quarter 2024 Bermuda, May 15, 2024 Key information relating to return of capital and dividend to be paid by Avance Gas Holding Ltd. for the first quarter 2024 is specified as per below. The distribution of return of capital will be made from the Company’s Contributed Surplus account which consists of previously paid in share premium transferred from the Company’s Share Premium account. Return of capital: $0.99 Dividend amount: $1.16 Declared currency: USD Last day including right: May 22, 20...
Avance Gas Holding Ltd: First Quarter 2024 Earnings Release
Avance Gas Holding Ltd: First Quarter 2024 Earnings Release BERMUDA, May 15, 2024 – Avance Gas Holding Ltd (OSE: AGAS) (“Avance Gas” or the “Company”) today reports unaudited results for the first quarter 2024. HIGHLIGHTS The average time charter equivalent (TCE) rate basis discharge-to-discharge was $60,900/day, compared to $76,200/day for the fourth quarter 2023.TCE/day on load-to-discharge basis was $78,800/day compared to $71,900/day for the fourth quarter 2023. Adjustment related to load-to-discharge was positive $21 million or $17,900/day ...
Coloplast udvider Luja™-portefølje med nyt kateter til kvinder
Coloplast udvider Luja™-portefølje med nyt kateter til kvinder Engangskateteret gør det muligt for kvinder at tømme blæren i et frit flow1, hvilket nedsætter risikoen for urinvejsinfektioner2. Luja-platformen er med sin Micro-hole Zone Technology en ny generation af intermitterende engangskatetre til mennesker med behov for hjælp til at tømme deres blære. Efter en vellykket lancering af Luja til mandlige kateterbrugere lancerer Coloplast nu Luja til kvinder. ”Vi har modtaget rigtig god feedback for Luja til mænd i vores produktevalueringer. Næsten alle sundhedsprofessionelle anbefaler kat...
Coloplast expands its Luja™ portfolio with next generation catheter fo...
Coloplast expands its Luja™ portfolio with next generation catheter for women The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and sev...
Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our ...
Avance Gas Holding Ltd (AGAS): Successfully completed the sale of our sixth dual fuel VLGC newbuilding Hamilton, Bermuda May 10, 2024 Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) announce the successful sale of the Very Large Gas Carrier (VLGC) newbuilding hull 2368 in connection with the delivery of her from Hanwha Ocean yard in South Korea. The VLGC with the intended name Avance Pollux was sold for an agreed price of $120 million less broker commission as previously announced in a press release dated December 8, 2023. The Company expect to record a book gain an...
- ABGSC Healthcare Research
- Morten Larsen
- Rune Majlund Dahl
Coloplast (Buy, TP: DKK1050.00) - Next up: ‘Meet the Management’
Q2 organic growth of 7.5% YOY was in line with our forecast and consensus, but the EBIT margin (b.s.i.) of 27.2% missed. Coloplast revised its 2023/24 reported revenue growth guidance to 10–11% (previously c11%) on FX, but kept its c8% organic growth and 27–28% EBIT margin (b.s.i.) guidance. At the upcoming ‘Meet the Management’ event, we expect an update on its clinical performance programme and a deep-dive into Kerecis. We reiterate our BUY and DKK1,050 target price.
- Helene Kvilhaug Brøndbo
Cambi (Buy, TP: NOK20.00) - Preparing for higher activity
We consider the project delays in Q1 a bump in the road, and expect the business case to remain strong on increasing awareness and commercial interest for thermal hydrolysis, and an expanding pipeline of potential projects, supported by a backlog with 40% in the engineering phase set to enter manufacturing this year. We reiterate our BUY and NOK20 target price, and find the stock attractive at 2024–2025e EV/EBITDAs of 8.5–7.9x, versus its waste management and recycling peer group at ~12x.
Avance Gas agrees one-year Time Charter for Chinook
Avance Gas agrees one-year Time Charter for Chinook Hamilton, Bermuda May 7, 2024 Avance Gas Holding Ltd ("Avance Gas" or the "Company") (OSE: AGAS) today announce that it has extended the variable Time Charter for the VLGC Chinook (built 2015) expiring July 2024 by one year with an energy major. The new Time Charter period thus aligning with the drydocking window for the ship expected to take place mid-2025. For further queries, please contact: Media contact: Øystein Kalleklev, CEO, Tel: Investor and Analyst contact: Randi Navdal Bekkelund, CFO, Tel: ABOUT AVANCE G...
- Martin Marandon-Carlhian
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Martin Marandon-Carlhian
- Stephane Houri
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Oliver Metzger
Coloplast : Q2 review – Top and bottom line a slight miss, focus on LC...
>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast styrker stomiporteføljen med tre nye produktlanceringer
Coloplast styrker stomiporteføljen med tre nye produktlanceringer Selskabet har fået refusionsgodkendelse i Storbritannien for Heylo™, verdens første digitale notifikationssystem til at opdage lækage, og udvider samtidig sin SenSura® Mio-produktserie med to nye lanceringer. Da vi lancerede vores 2025-strategi, Strive25, satte vi et klart mål om at hæve behandlingsstandarden for vores brugere og bringe nye produkter hurtigere til markedet. Jeg glæder mig over at se, at vores innovationsteam bliver ved med at levere, senest med lanceringen af disse tre nye stomiprodukter, fortæller Colopl...
Coloplast strengthens ostomy care portfolio with three significant pro...
Coloplast strengthens ostomy care portfolio with three significant product launches The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products. As part of our 2025 strategy, Strive25, we set an ambition to significantly raise the standard of care for our users and bring new products to market at a higher pace. I am excited to see that our Innovation unit continues to deliver on this commitment, latest with these three new products in Ostomy Care, says Executiv...
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, ...
Coloplast A/S - Selskabsmeddelelse nr. 02/2024 - Regnskabsmeddelelse, 1. halvår 2023/24 H1 2023/24Regnskabsmeddelelse, 1. halvår 2023/241. oktober 2023 – 31. marts 2024 Coloplast leverede et solidt 2. kvartal med 8% organisk vækst og en overskudsgrad1) på 27%. Den rapporterede omsætning målt i danske kroner steg 9% med 4 procentpoint bidrag fra Kerecis (underliggende vækst på ca. 35%), delvist udlignet af valutaer. Den organiske vækst pr. forretningsområde var 7% i Stomi, 8% i Kontinens, 13% i Stemme og Respiratorisk Pleje, 8% i Avanceret Sårpleje (8% i Avancerede Sårbandag...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H...
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24 H1 2023/24Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies. Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional Urology 5%.Continu...
- Jørgen Lian
Avance Gas (Hold, TP: NOK172.00) - Set for Q1 beat, high 2024e DPS
Spot rates remain above USD50k/day, supported by US inventories c14% above the 5-year average. We believe this provides a solid outlook for 2024 VLGC earnings, backed by the FFA for the rest of the year at cUSD55k/day. We forecast a 2024 DPS of cNOK45, or 28% of the current share price. However, given the recent share price rise, we find the stock fully valued at a P/NAV of 1.05x. We have downgraded to HOLD (BUY), but have raised our target price to NOK172 (168).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.